Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.44 |
| ▸ | BTK | Q06187 | 7/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | TEC | P42680 | 1/20 | 0.37 |
| ▸ | TXK | P42681 | 1/20 | 0.37 |
| ▸ | BLK | P51451 | 1/20 | 0.37 |
| ▸ | BMX | P51813 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.37 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723499 | 0.87 | HTT (0.43) | METCYSLTR1MAPK14EPHX1FFAR1 | |
| SCHEMBL21082374 | 0.85 | EGFR (0.34) | EGFRBTKMETERBB2TEC | |
| SCHEMBL722213 | 0.85 | BTK (0.59) | EGFRBTKERBB2TECTXK | |
| SCHEMBL724108 | 0.84 | EGFR (0.47) | EGFRBTK | |
| SCHEMBL723785 | 0.83 | BTK (0.56) | EGFRBTKERBB2TECTXK | |
| SCHEMBL721787 | 0.81 | TGM2 (0.52) | EGFRBTKERBB2TECTXK | |
| SCHEMBL18869138 | 0.80 | BTK (0.65) | EGFRBTKJAK3FFAR1 | |
| SCHEMBL723014 | 0.79 | EGFR (0.58) | EGFRBTKJAK3TGM2 | |
| SCHEMBL723500 | 0.78 | BTK (0.48) | EGFRBTKERBB2TECTXK | |
| SCHEMBL14165631 | 0.78 | BTK (0.64) | EGFRBTKMAPK14EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | claimed |
| US-20230100137-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC (US) | 2023-03-30 | — | — | US | disclosed |
| US-11318138-B2 | Methods for treating B cell proliferative disorders | CORNELL UNIVERSITY (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210177854-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC | 2021-06-17 | — | — | US | disclosed |
| US-20210145835-A1 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER | PHARMACYCLICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210121463-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200397895-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | PHARMACYCLICS LLC (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200368235-A1 | IBRUTINIB COMBINATION THERAPY | PHARMACYCLICS LLC (US) | 2020-11-26 | — | — | US | disclosed |
| US-10695350-B2 | Methods of treating and preventing graft versus host disease | PHARMACYCLICS LLC (US) | 2020-06-30 | — | — | US | disclosed |
| US-20150044217-A1 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | disclosed |
| US-20150044217-A1 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | disclosed |
| US-20150038518-A1 | METHODS FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2015-02-05 | — | — | US | disclosed |
| US-20150038518-A1 | METHODS FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2015-02-05 | — | — | US | disclosed |
| WO-2014159745-A1 | COMBINATIONS OF BRUTON'S TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121463-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | BLK, DCK, CILK1 | EGFR 2307/4885BTK 8/4885MET 2255/4885 |
| US-20150038518-A1 | METHODS FOR THE TREATMENT OF SOLID TUMORS | HDAC1, HDAC4, HDAC2 | EGFR 1866/4885BTK 1268/4885MET 1098/4885 |
| US-11318138-B2 | Methods for treating B cell proliferative disorders | CDK4, BCL6, BCL6B | EGFR 1336/4885BTK 4/4885MET 985/4885 |
| US-10695350-B2 | Methods of treating and preventing graft versus host disease | BLK, DCK, CILK1 | EGFR 2307/4885BTK 8/4885MET 2255/4885 |
| US-20210145835-A1 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER | ERBB2, EGFR, ERBB3 | EGFR 2/4885BTK 10/4885MET 12/4885 |
| US-20210177854-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | FCGR3B, BTK, IGLV6-57 | EGFR 1605/4885BTK 2/4885MET 522/4885 |
| US-20150044217-A1 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER | ERBB2, EGFR, ERBB3 | EGFR 2/4885BTK 10/4885MET 12/4885 |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | SYK, FCGRT, SSB | EGFR 1317/4885BTK 4/4885MET 1482/4885 |
| US-20230100137-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | FCGR3B, BTK, IGLV6-57 | EGFR 1605/4885BTK 2/4885MET 522/4885 |
| US-20200397895-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | BTK, LCK, LYN | EGFR 544/4885BTK 1/4885MET 2479/4885 |
| US-20200368235-A1 | IBRUTINIB COMBINATION THERAPY | BTK, SYK, LYN | EGFR 679/4885BTK 1/4885MET 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.